bitopertin + selective serotonin reuptake inhibitor

This is a combination therapy of **bitopertin**, a glycine transporter 1 (GlyT1) inhibitor, and a **selective serotonin reuptake inhibitor (SSRI)**, a class of antidepressants. Bitopertin is a small molecule that inhibits glycine reuptake, increasing glycine levels primarily to potentiate NMDA receptor signaling in the central nervous system, and is under development as a disease-modifying therapy for erythropoietic protoporphyria (EPP)[1][2][3][4][7]. SSRIs act by inhibiting serotonin reuptake, increasing serotonin levels in the synaptic cleft to treat depression and related disorders. This combination may have been previously considered for modulation of negative symptoms in schizophrenia, but bitopertin's development for this indication was discontinued after unsuccessful trial results[1][4]. The canonical name refers to a therapy composed of both agents used concomitantly, not a proprietary combination drug.

Other names

bitopertinselective serotonin reuptake inhibitor-Hoffmann-La Roche-Obsessive-Compulsive Disorder